These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38554797)

  • 1. Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor.
    Mansour HM; Mohamed AF; Khattab MM; El-Khatib AS
    Brain Res; 2024 Jul; 1834():148893. PubMed ID: 38554797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: Potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease.
    Mansour HM; F Mohamed A; Khattab MM; El-Khatib AS
    Eur J Pharmacol; 2023 Sep; 954():175875. PubMed ID: 37385578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of a standardized extract of Centella asiatica ECa233 in rotenone-induced parkinsonism rats.
    Teerapattarakan N; Benya-Aphikul H; Tansawat R; Wanakhachornkrai O; Tantisira MH; Rodsiri R
    Phytomedicine; 2018 May; 44():65-73. PubMed ID: 29895494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Neurotrophic and supportive actions in the substantia nigra pars compacta.
    Cankara FN; Günaydın C; Bilge SS; Özmen Ö; Kortholt A
    Neurosci Lett; 2020 Nov; 738():135308. PubMed ID: 32932183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymoquinone exerts neuroprotective effect in animal model of Parkinson's disease.
    Ebrahimi SS; Oryan S; Izadpanah E; Hassanzadeh K
    Toxicol Lett; 2017 Jul; 276():108-114. PubMed ID: 28526446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells.
    Alabi AO; Ajayi AM; Ben-Azu B; Omorobge O; Umukoro S
    Metab Brain Dis; 2019 Dec; 34(6):1723-1736. PubMed ID: 31463866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
    Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R
    Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM; Sherer TB; Greenamyre JT
    Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipramine and amitriptyline ameliorate the rotenone model of Parkinson's disease in rats.
    Kandil EA; Abdelkader NF; El-Sayeh BM; Saleh S
    Neuroscience; 2016 Sep; 332():26-37. PubMed ID: 27365173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins.
    Rahimmi A; Khosrobakhsh F; Izadpanah E; Moloudi MR; Hassanzadeh K
    Brain Res Bull; 2015 Apr; 113():34-40. PubMed ID: 25732239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca(2+) dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat.
    Avalos-Fuentes A; Albarrán-Bravo S; Loya-Lopéz S; Cortés H; Recillas-Morales S; Magaña JJ; Paz-Bermúdez F; Rangel-Barajas C; Aceves J; Erlij D; Florán B
    Neurobiol Dis; 2015 Feb; 74():336-46. PubMed ID: 25517101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats.
    Bülbül M; Sinen O; Özkan A; Aslan MA; Ağar A
    Exp Neurol; 2019 Jul; 317():78-86. PubMed ID: 30825442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective mechanism of Syringic acid in an experimental model of Parkinson's disease.
    Güzelad Ö; Özkan A; Parlak H; Sinen O; Afşar E; Öğüt E; Yıldırım FB; Bülbül M; Ağar A; Aslan M
    Metab Brain Dis; 2021 Jun; 36(5):1003-1014. PubMed ID: 33666819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease.
    Wang T; Wang L; Li C; Han B; Wang Z; Li J; Lv Y; Wang S; Fu F
    Neurochem Res; 2017 May; 42(5):1325-1332. PubMed ID: 28097465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
    Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
    Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson's disease therapy.
    Zaitone SA; Ahmed E; Elsherbiny NM; Mehanna ET; El-Kherbetawy MK; ElSayed MH; Alshareef DM; Moustafa YM
    Pharmacol Rep; 2019 Feb; 71(1):32-41. PubMed ID: 30368226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
    Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
    Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EGF receptor inhibits the signaling of dopamine D
    Sun N; Zhang X; Zhang X; Kim KM
    Biochem Biophys Res Commun; 2017 Aug; 489(4):515-522. PubMed ID: 28579429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.